Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
Ann Hematol
; 103(5): 1775-1777, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38556531
ABSTRACT
Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA occurring after ABO-matched allo-HSCT in a refractory/relapsed acute myeloid leukemia (R/R AML) patient. In this case, the patient received a combination treatment of Gilteritinib, Venetoclax, and Azacitidine. Remarkably, this treatment not only reduced myeloblasts but also facilitated the restoration of erythroid hematopoiesis.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirazinas
/
Sulfonamidas
/
Enfermedades de la Médula Ósea
/
Leucemia Mieloide Aguda
/
Aplasia Pura de Células Rojas
/
Trasplante de Células Madre Hematopoyéticas
/
Compuestos Bicíclicos Heterocíclicos con Puentes
/
Compuestos de Anilina
Límite:
Humans
Idioma:
En
Revista:
Ann Hematol
Asunto de la revista:
HEMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
China